Blinatumomab bi-specific T-cell engager (BiTE) drug. Targets CD19 and CD3; indicated for the treatment of acute lymphoblastic leukemia (ALL). Generic

---

Blinatumomab bi-specific T-cell engager (BiTE) drug. Targets CD19 and CD3; indicated for the treatment of acute lymphoblastic leukemia (ALL). Generic name and stylized antibody.

---

Size: 9000px × 3049px
Photo credit: © molekuul.be / Alamy / Afripics
License: Royalty Free
Model Released: No

Keywords: -cell, acute, antibody, biological, biosimilar, biotech, biotechnology, bispecific, bite, blinatumomab, cd19, cd3, chromosome, disease, drug, engager, immunoglobulin, immunology, infusion, injection, inn, leukemia, lymphoblastic, mab, malignant, monoclonal, nomenclature, oncology, peptide, philadelphia, protein